ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
SK Pharmteco, a pharmaceutical contract development and manufacturing firm owned by the South Korean conglomerate SK, has appointed Joerg Ahlgrimm as CEO. Ahlgrimm, former head of operations for pharmaceuticals and biotechnology at Lonza and most recently CEO of the Center for Breakthrough Medicine, will replace Aslam Malik, who has been CEO at Pharmteco predecessor Ampac Fine Chemicals since 2005. SK purchased Ampac before the formation of Pharmteco in 2018. In January, SK made a $350 million equity investment in the Center for Breakthrough Medicines, which is a gene therapy services firm.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X